Holen Sie sich die Stockscreener-App
14.05
0.00%
0.00
Handel nachbörslich:
13.78
-0.27
-1.92%
Celcuity Inc Aktie (CELC) Neueste Nachrichten
What analysts say about Celcuity Inc. stockExceptional gains - jammulinksnews.com
Celcuity Inc. Stock Analysis and ForecastSuperior investment outcomes - Autocar Professional
Is Celcuity Inc. a good long term investmentFree Stock Market Real-Time Monitoring - jammulinksnews.com
What drives Celcuity Inc. stock priceSuperior stock growth - jammulinksnews.com
why celcuity inc. stock attracts strong analyst attentionTop Rated Trade Entries - Newser
What makes Celcuity Inc. stock price move sharplyFree Elite Traders Group - Newser
How Celcuity Inc. stock performs during market volatilityBreakout Momentum Alerts - Newser
Why Celcuity Inc. stock attracts strong analyst attentionProven High Yield Signals - Newser
Celcuity receives U.S. patent for gedatolisib dosing regimen - Investing.com Australia
How To Trade (CELC) - news.stocktradersdaily.com
Celcuity Soars 17.16% on New Patent for Breast Cancer Drug - AInvest
Celcuity Receives New Patent for Gedatolisib - MarketScreener
Celcuity receives U.S. patent for gedatolisib dosing regimen By Investing.com - Investing.com South Africa
Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042 - The Manila Times
Celcuity, Inc. (NASDAQ:CELC) Receives $28.40 Average Target Price from Analysts - Defense World
Celcuity projects $2B revenue potential for gedatolisib in second-line breast cancer market - MSN
Celcuity(CELC) Shares Soar 4.70% on Phase 2 Trial Success - AInvest
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention - PentictonNow
Learn to Evaluate (CELC) using the Charts - news.stocktradersdaily.com
Stifel Initiates Celcuity(CELC.US) With Buy Rating, Announces Target Price $30 - 富途牛牛
Celcuity (NASDAQ:CELC) Given Buy Rating at Needham & Company LLC - Defense World
Celcuity Announces Promising Phase 1 Gedatolisib Results - TipRanks
Celcuity reports positive early data for gedatolisib in cancer trials By Investing.com - Investing.com UK
New Clinical Data: Celcuity's Cancer Drug Achieves Breakthrough Results in Dual Phase Studies - Stock Titan
Rhumbline Advisers Has $427,000 Stock Position in Celcuity, Inc. (NASDAQ:CELC) - Defense World
Analysts Set Celcuity Inc. (NASDAQ:CELC) Price Target at $30.80 - Defense World
Wealth Enhancement Advisory Services LLC Grows Stock Holdings in Celcuity Inc. (NASDAQ:CELC) - Defense World
Stocks in play: Roots Corp. - The Globe and Mail
(CELC) Trading Advice - news.stocktradersdaily.com
Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - Revista ADVFN
Cisco Powers AI-Ready Data Centers, From Hyperscale to Enterprise - The Globe and Mail
Millennium Management LLC Has $519,000 Stock Holdings in Celcuity Inc. (NASDAQ:CELC) - Defense World
Two Sigma Investments LP Has $679,000 Stock Holdings in Celcuity Inc. (NASDAQ:CELC) - Defense World
Nuveen Asset Management LLC Grows Position in Celcuity Inc. (NASDAQ:CELC) - Defense World
Ballard announces 1.5 MW fuel cell engine order for Sierra Northern Railway - The Globe and Mail
Citadel Advisors LLC Buys New Stake in HUHUTECH International Group Inc. (NASDAQ:HUHU) - Defense World
Two Sigma Advisers LP Decreases Stock Position in Celcuity Inc. (NASDAQ:CELC) - Defense World
3.30%
1.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):